Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation (501Y.V2 lineage, B.1.351; P.1 lineage, B.1.1.28.1; Kent variant; B.1.526 lineage)

Order information

Package	Catalog No.	Price(In USD)	Qty (Quantity)	Sum(In USD)
1mg	GMP-V-2019nCoV-Smu-017-1mg	5990
10mg	GMP-V-2019nCoV-Smu-017-10mg	38790
100mg	GMP-V-2019nCoV-Smu-017-100mg	258000
≥100mg	GMP-V-2019nCoV-Smu-017-xmg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Accession Number	QHD43415.1
Expression platform	2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
Isotypes	Mamamlian (human cell)
Tag	C-His
Products description	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation (501Y.V2 lineage, B.1.351; P.1 lineage, B.1.1.28.1; Kent variant; B.1.526 lineage) was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.
Bioactivity validation	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
Purity	Purity: ≥95% (SDS-PAGE)
Application	Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass	35kDa
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation
(501Y.V2 lineage, B.1.351; P.1 lineage, B.1.1.28.1; Kent variant; B.1.526 lineage)

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein.

The SARS-CoV-2 (2019nCOV) spike-E484K mutation occurs in different variants and has already been found in the South African variant (B.1.351lineage) and Brazilian variant (B.1.1.28 lineage). On 1st February, Public Health England (PHE) announced that the Covid-19 Genomics (COG-UK) consortium had identified this same E484K mutation in 11 samples carrying the UK variant B.1.1.7 lineage (sometimes called the Kent variant), after analyzing 214 159 sequences. Besides, the E484K mutation also occurs in the B.1.526 lineage that has recently become prevalent in New York State, particularly in the New York City metropolitan area.

Lineage	The UK variant B.1.1.7 lineage	The South African variant B.1.351 lineage	The Brazilian variant B.1.1.28 lineage	The Kent variant (B.1.1.7 plus E484K)	The New York variant B.1.526 lineage
Spike E484K mutation	-	+	+	+	+

The E484K mutation in the spike protein is located within the receptor-binding domain (RBD). It is called an escape mutation because it helps the virus slip past the body’s immune defenses. Ravindra Gupta at the University of Cambridge and colleagues have confirmed that the new B.1.1.7 plus E484K variant substantially increases the amount of serum antibody needed to prevent infection of cells. The mutation E484K has now been identified in the UK fast-spreading variant, prompting fears the virus is evolving further and could become resistant to vaccines.

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Validated in functional ELISA, other immunoassays, The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.